Nods for Atezolizumab and Nivolumab from FDA

Nods for Atezolizumab and Nivolumab from FDA

The FDA has conditionally approved atezolizumab, the first PD-L1 inhibitor, for metastatic urothelial carcinoma, along with a companion diagnostic, the Ventana PD-L1 (SP142) assay. The agency has also expanded nivolumab's indications to include classical Hodgkin lymphoma, making this PD-1 inhib...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer discovery 2016-08, Vol.6 (8), p.811-811
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 811
container_issue 8
container_start_page 811
container_title Cancer discovery
container_volume 6
description The FDA has conditionally approved atezolizumab, the first PD-L1 inhibitor, for metastatic urothelial carcinoma, along with a companion diagnostic, the Ventana PD-L1 (SP142) assay. The agency has also expanded nivolumab's indications to include classical Hodgkin lymphoma, making this PD-1 inhibitor the first to be approved for a hematologic malignancy.
doi_str_mv 10.1158/2159-8290.CD-NB2016-080
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1809047449</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1809047449</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-892e510ff1e69630b6b2ca9c971dadf7dd17a9decb33b1dbd55efb51a253580f3</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EolXpK0COHEjxb2wfS0oBqSoXOFt2bEtBSV3sBok-fRNaupfd1c7MSh8AdwjOEGLiESMmc4ElnJWLfP2EISpyKOAFGJ8vl-eZ0xGYpvQF-6KSMsivwQhzghkWZAwe1sGmzIeYzXduH5p637XaZHpjs3X9E5q_zcfQZsvF_AZced0kNz31CfhcPn-Ur_nq_eWtnK_yClOyy4XEjiHoPXKFLAg0hcGVlpXkyGrrubWIa2ldZQgxyBrLmPOGIY0ZYQJ6MgH3x9xtDN-dSzvV1qlyTaM3LnRJIQElpJxS2Uv5UVrFkFJ0Xm1j3er4qxBUAy01cFADE1Uu1JGW6mn1ztvTk860zp59_2zIAZwcZFc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1809047449</pqid></control><display><type>article</type><title>Nods for Atezolizumab and Nivolumab from FDA</title><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><description>The FDA has conditionally approved atezolizumab, the first PD-L1 inhibitor, for metastatic urothelial carcinoma, along with a companion diagnostic, the Ventana PD-L1 (SP142) assay. The agency has also expanded nivolumab's indications to include classical Hodgkin lymphoma, making this PD-1 inhibitor the first to be approved for a hematologic malignancy.</description><identifier>ISSN: 2159-8274</identifier><identifier>EISSN: 2159-8290</identifier><identifier>DOI: 10.1158/2159-8290.CD-NB2016-080</identifier><identifier>PMID: 27325283</identifier><language>eng</language><publisher>United States</publisher><ispartof>Cancer discovery, 2016-08, Vol.6 (8), p.811-811</ispartof><rights>2016 American Association for Cancer Research.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c243t-892e510ff1e69630b6b2ca9c971dadf7dd17a9decb33b1dbd55efb51a253580f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27325283$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><title>Nods for Atezolizumab and Nivolumab from FDA</title><title>Cancer discovery</title><addtitle>Cancer Discov</addtitle><description>The FDA has conditionally approved atezolizumab, the first PD-L1 inhibitor, for metastatic urothelial carcinoma, along with a companion diagnostic, the Ventana PD-L1 (SP142) assay. The agency has also expanded nivolumab's indications to include classical Hodgkin lymphoma, making this PD-1 inhibitor the first to be approved for a hematologic malignancy.</description><issn>2159-8274</issn><issn>2159-8290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9kM1OwzAQhC0EolXpK0COHEjxb2wfS0oBqSoXOFt2bEtBSV3sBok-fRNaupfd1c7MSh8AdwjOEGLiESMmc4ElnJWLfP2EISpyKOAFGJ8vl-eZ0xGYpvQF-6KSMsivwQhzghkWZAwe1sGmzIeYzXduH5p637XaZHpjs3X9E5q_zcfQZsvF_AZced0kNz31CfhcPn-Ur_nq_eWtnK_yClOyy4XEjiHoPXKFLAg0hcGVlpXkyGrrubWIa2ldZQgxyBrLmPOGIY0ZYQJ6MgH3x9xtDN-dSzvV1qlyTaM3LnRJIQElpJxS2Uv5UVrFkFJ0Xm1j3er4qxBUAy01cFADE1Uu1JGW6mn1ztvTk860zp59_2zIAZwcZFc</recordid><startdate>201608</startdate><enddate>201608</enddate><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201608</creationdate><title>Nods for Atezolizumab and Nivolumab from FDA</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-892e510ff1e69630b6b2ca9c971dadf7dd17a9decb33b1dbd55efb51a253580f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>online_resources</toplevel><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nods for Atezolizumab and Nivolumab from FDA</atitle><jtitle>Cancer discovery</jtitle><addtitle>Cancer Discov</addtitle><date>2016-08</date><risdate>2016</risdate><volume>6</volume><issue>8</issue><spage>811</spage><epage>811</epage><pages>811-811</pages><issn>2159-8274</issn><eissn>2159-8290</eissn><abstract>The FDA has conditionally approved atezolizumab, the first PD-L1 inhibitor, for metastatic urothelial carcinoma, along with a companion diagnostic, the Ventana PD-L1 (SP142) assay. The agency has also expanded nivolumab's indications to include classical Hodgkin lymphoma, making this PD-1 inhibitor the first to be approved for a hematologic malignancy.</abstract><cop>United States</cop><pmid>27325283</pmid><doi>10.1158/2159-8290.CD-NB2016-080</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2159-8274
ispartof Cancer discovery, 2016-08, Vol.6 (8), p.811-811
issn 2159-8274
2159-8290
language eng
recordid cdi_proquest_miscellaneous_1809047449
source American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title Nods for Atezolizumab and Nivolumab from FDA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T01%3A24%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nods%20for%20Atezolizumab%20and%20Nivolumab%20from%20FDA&rft.jtitle=Cancer%20discovery&rft.date=2016-08&rft.volume=6&rft.issue=8&rft.spage=811&rft.epage=811&rft.pages=811-811&rft.issn=2159-8274&rft.eissn=2159-8290&rft_id=info:doi/10.1158/2159-8290.CD-NB2016-080&rft_dat=%3Cproquest_cross%3E1809047449%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1809047449&rft_id=info:pmid/27325283&rfr_iscdi=true